Meredith McGuire

Dr McGuire is an accomplished cell and molecular biologist specializing in drug metabolism, clinical research, and regulatory science. Her PhD research at Johns Hopkins University revealed a novel mechanism by which PGRMC1 regulates cytochrome P450-mediated drug metabolism, significantly advancing the field of pharmacology. With over 10 years of experience across academic and regulatory settings, she has cultivated a unique combination of fundamental science expertise and practical regulatory acumen. At the FDA, as an ORISE post-doctoral fellow in the Office of Generic Drugs, she led a high-impact project examining drug swallowability that directly influenced new agency policy. Her regulatory science work enhanced the clinical safety of generic medications through management of clinical studies on drug-excipient interactions and detailed analysis of post-marketing adverse events related to generic product formulations. Dr McGuire has also made valuable contributions to oncology research, identifying SCAP, a key regulator of lipid homeostasis, as a promising therapeutic target for pancreatic cancer. Her technical proficiency spans a wide range of methodologies including CRISPR genome editing, oncology animal models, and clinical study management. Her work has been recognized with competitive grants from the American Heart Association and National Institutes of Health.

Dr McGuire has authored five peer-reviewed publications, including two first-author articles and a first-author invited review. Her work has been published in journals such as the Journal of Biological Chemistry, Pharmacology & Therapeutics, and the International Journal of Pharmaceutics and she has delivered poster presentations at the American Society for Biochemistry and Molecular Biology and the American College of Clinical Pharmacology annual meetings.

Dr McGuire has experience editing research manuscripts for colleagues and mentees, providing constructive feedback to improve clarity, scientific accuracy, and logical flow. As a post-doctoral fellow at the FDA, she reviewed and edited technical documents including clinical study protocols, informed consent documents, and case report forms, ensuring both scientific rigor and accessibility for diverse audiences. She has also contributed to the peer review process as a reviewer evaluating manuscripts in the area of cytochrome P450 biology for BMC Genomics, with her editorial approach emphasizing maintaining scientific precision while enhancing readability and improving grammar. Dr McGuire joined Edanz as an Editor in 2025.

Dr McGuire has demonstrated strong scientific writing skills throughout her academic and professional career, authoring multiple peer-reviewed research articles in respected journals. As well as writing successful grant proposals, she contributed to technical writing for regulatory documents (e.g., INDs) and clinical study documents while at the FDA.